Live feed08:00:00·14dPRReleasevia QuantisnowPfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal CancerByQuantisnow·Wall Street's wire, on your screen.PFE· Pfizer Inc.Health Care